189 related articles for article (PubMed ID: 22644307)
1. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival.
Choi CH; Choi JJ; Park YA; Lee YY; Song SY; Sung CO; Song T; Kim MK; Kim TJ; Lee JW; Kim HJ; Bae DS; Kim BG
Br J Cancer; 2012 Jun; 107(1):91-9. PubMed ID: 22644307
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.
Têtu B; Popa I; Bairati I; L'Esperance S; Bachvarova M; Plante M; Harel F; Bachvarov D
Mod Pathol; 2008 Aug; 21(8):1002-10. PubMed ID: 18500265
[TBL] [Abstract][Full Text] [Related]
3. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
[TBL] [Abstract][Full Text] [Related]
4. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract][Full Text] [Related]
5. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
7. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
[TBL] [Abstract][Full Text] [Related]
8. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
9. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
10. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
11. Who are the long-term survivors of high grade serous ovarian cancer?
Hoppenot C; Eckert MA; Tienda SM; Lengyel E
Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
[TBL] [Abstract][Full Text] [Related]
12. Comparative proteomic analysis of advanced serous epithelial ovarian carcinoma: possible predictors of chemoresistant disease.
Kim SW; Kim S; Nam EJ; Jeong YW; Lee SH; Paek JH; Kim JH; Kim JW; Kim YT
OMICS; 2011 May; 15(5):281-92. PubMed ID: 21332407
[TBL] [Abstract][Full Text] [Related]
13. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
14. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
15. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.
Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M
Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
[TBL] [Abstract][Full Text] [Related]
19. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
[TBL] [Abstract][Full Text] [Related]
20. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]